Substance under pre-clinical research

YS110

YS110 has a potential activity on various types of immune disorders such as rheumatoid arthritis, systemic lupus erythematosus,multiple sclerosis and graft-versus-host diseases.

Anti- human IL26 monoclonal antibody (under the patent application by Pr. Morimoto’s Lab.)

IL26 was identified as an IL10 family of cytokine, which has been observed as activated in the chronic inflammatory lesions of lung fibroses, liver scleroses and scleroderma, etc.. The anti-human IL26 monoclonal antibody affects IL26 directory to inhibit a function of IL26, resulting in the treatment of organs’ fibroses and scleroses,such as COPD, etc.. This antibody is expected to be a new therapeutic agent for the treatment of those diseases. The high risk of cancer incidence often associated with organs’ fibroses and scleroses. It has been observed that our established antibody also inhibits proliferation, metastases and invasion of tumor cells in the preclinical study. Therefore this antibody is also expected to be a new anti-cancer agent without influencing on normal organs.The possible application of the human monoclonal antibody against IL26 is summarized as shown in the Fig.